Elusys awarded $16 million to continue anthrax treatment development
This contract is in support of the development of a freeze-dried variant of their current fluid treatment candidate for anthrax infection. This would allow the company to expand the shelf life of the treatment option; the company states that it has the potential to be added to the U.S. Strategic National Stockpile (SNS).
"We are pleased to have the ongoing support of the U.S. government, to further improve the potential usefulness of Anthim to protect the American public, military personnel and first responders in an emergency," Elizabeth Posillico, president and CEO of Elusys, said. "A lyophilized form of Anthim has the potential for longer shelf life and improved temperature stability in the field, as well as greater efficiencies in managing anthrax antitoxins in the SNS."
Anthim consists of monoclonal antibodies that has been formulated to act as an anti-toxin to inhaled forms of anthrax. The company states that this candidate is the only one of its kind in the late stages of development. The company has received approximately $195 million in BARDA development contracts relating to Anthim.